KR102395342B1 - 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법 - Google Patents

레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법 Download PDF

Info

Publication number
KR102395342B1
KR102395342B1 KR1020187032832A KR20187032832A KR102395342B1 KR 102395342 B1 KR102395342 B1 KR 102395342B1 KR 1020187032832 A KR1020187032832 A KR 1020187032832A KR 20187032832 A KR20187032832 A KR 20187032832A KR 102395342 B1 KR102395342 B1 KR 102395342B1
Authority
KR
South Korea
Prior art keywords
rtx
trpv1
receptor agonist
pharmaceutical composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187032832A
Other languages
English (en)
Korean (ko)
Other versions
KR20190029511A (ko
Inventor
어빙 에이치. 주커
한쥔 왕
Original Assignee
보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 filed Critical 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카
Priority to KR1020227014423A priority Critical patent/KR102508022B1/ko
Publication of KR20190029511A publication Critical patent/KR20190029511A/ko
Application granted granted Critical
Publication of KR102395342B1 publication Critical patent/KR102395342B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187032832A 2016-04-13 2017-04-13 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법 Active KR102395342B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227014423A KR102508022B1 (ko) 2016-04-13 2017-04-13 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322079P 2016-04-13 2016-04-13
US62/322,079 2016-04-13
PCT/US2017/027480 WO2017180907A1 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227014423A Division KR102508022B1 (ko) 2016-04-13 2017-04-13 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20190029511A KR20190029511A (ko) 2019-03-20
KR102395342B1 true KR102395342B1 (ko) 2022-05-10

Family

ID=60039929

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187032832A Active KR102395342B1 (ko) 2016-04-13 2017-04-13 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법
KR1020227014423A Active KR102508022B1 (ko) 2016-04-13 2017-04-13 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227014423A Active KR102508022B1 (ko) 2016-04-13 2017-04-13 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법

Country Status (8)

Country Link
US (3) US20170296506A1 (enExample)
EP (1) EP3442523A4 (enExample)
JP (3) JP6980694B2 (enExample)
KR (2) KR102395342B1 (enExample)
CN (2) CN120114438A (enExample)
AU (1) AU2017248665B2 (enExample)
IL (2) IL262328B2 (enExample)
WO (1) WO2017180907A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490745A (zh) 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
WO2020154261A1 (en) 2019-01-22 2020-07-30 Sorrento Therapeutics, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin
CN116744867A (zh) * 2020-08-11 2023-09-12 索伦托药业有限公司 通过神经消融治疗肺部炎性疾病
WO2022245791A1 (en) * 2021-05-18 2022-11-24 Sorrento Therapeutics, Inc. Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150080460A1 (en) * 2013-09-18 2015-03-19 Board Of Regents Of The University Of Nebraska Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2607219A1 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity
SI1976521T1 (sl) * 2006-01-25 2015-06-30 Insys Therapeutics, Inc. Podjezično fentanilno pršilo
EP2007376B1 (en) * 2006-03-13 2013-05-08 Hadasit Medical Research Services And Development Ltd. Therapeutic uses of cannabidiol compounds
CN101522181A (zh) * 2006-10-04 2009-09-02 纽若科伊公司 诱导低体温药物在治疗局部缺血的应用
CN101951937A (zh) * 2007-12-21 2011-01-19 赫尔辛医疗股份公司 使用伊帕瑞林刺激胃肠系统动力的方法
US8846324B2 (en) * 2010-10-06 2014-09-30 Celltrend Gmbh In vitro method for diagnosing or predicting hypertension and/or early-stage cardiovascular end-organ damage by determining the concentration of soluble prorenin receptor
MX368865B (es) * 2013-09-17 2019-08-02 Vectus Biosystems Ltd Composiciones para el tratamiento de hipertension y/o fibrosis.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150080460A1 (en) * 2013-09-18 2015-03-19 Board Of Regents Of The University Of Nebraska Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin

Also Published As

Publication number Publication date
IL298314B1 (en) 2024-12-01
JP6980694B2 (ja) 2021-12-15
JP7341203B2 (ja) 2023-09-08
CA3020815A1 (en) 2017-10-19
IL262328B (en) 2022-12-01
US20250082605A1 (en) 2025-03-13
EP3442523A1 (en) 2019-02-20
IL298314B2 (en) 2025-04-01
KR20190029511A (ko) 2019-03-20
KR102508022B1 (ko) 2023-03-10
IL298314A (en) 2023-01-01
IL262328A (en) 2018-11-29
AU2017248665A1 (en) 2018-11-08
JP2022001608A (ja) 2022-01-06
US20220000837A1 (en) 2022-01-06
CN109562096A (zh) 2019-04-02
EP3442523A4 (en) 2019-12-04
IL262328B2 (en) 2023-04-01
KR20220062667A (ko) 2022-05-17
JP2023155365A (ja) 2023-10-20
CN120114438A (zh) 2025-06-10
US20170296506A1 (en) 2017-10-19
WO2017180907A1 (en) 2017-10-19
JP2019511536A (ja) 2019-04-25
AU2017248665B2 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
US20250082605A1 (en) Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin
Sharman et al. Vasopressin and its role in critical care
Gramling-Babb et al. Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience
Chierichini et al. The effect of norepinephrine versus epinephrine in irrigation fluid on the incidence of hypotensive/bradycardic events during arthroscopic rotator cuff repair with interscalene block in the sitting position
Lee et al. Combined spinal–epidural analgesia in labour: comparison of two doses of intrathecal bupivacaine with fentanyl
Dost et al. Pain management in minimally invasive cardiac surgery: a review of current clinical evidence
Schumacher et al. Treatment of venous malformations: first experience with a new sclerosing agent–a multicenter study
CA3020815C (en) Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
JP2620642B2 (ja) 麻薬性鎮痛剤とベンゾジアゼピンとを組み合わせて非経口投与した後に観察される平均血圧の低下を拮抗させるための医薬品
Venkateswaran et al. Management of postoperative pain
Royal Resiniferatoxin for permanent pain relief in cancer patients
Dasta Local anesthetics: evolving to a new standard of care
Sakura et al. Using ultrasound guidance in peripheral nerve blocks
d'Amours et al. Perioperative drugs and postoperative pain management
Sohn et al. Differential effects of rANF and chronic guanabenz to presynaptic and postsynaptic α2-adrenoceptor-mediated cardiovascular response in pithed rats
Staudt et al. Neuromodulation for Non-urologic Chronic Pain
Bujedo Which Epidural Opioid is More Suitable for Postoperative Pain Management
Huh Spinal cord stimulation for managing angina from coronary artery disease
Dauri et al. Anesthesia techniques in awake thoracic surgery
PAIN metabolic response to surgery in most studies (1, 5), but without effects on acute phase protein or leukocytic responses (1, 5). Intravenous, intraperi
Marzollaa et al. MR blockade protects against diet induced obesity, adipocyte dysfunction and cardiac inflammation in mice, through browning of the adipose organ and modulation of autophagy
Shalaby Ahmed Adel Abd El Fattah El beleehy
Brooker et al. Neuromodulation techniques for visceral pain from benign disorders
Aronson Drugs that affect autonomic functions or the extrapyramidal system
Dhingra Comparative Study of the Synergistic Effect and Safety Between Bupivacaine 0.5% with Dexmedetomidine and Bupivacaine 0.5% with Clonidine in Spinal Anaesthesia in Elective Lower Abdominal Surgeries

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181113

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200407

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210526

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211221

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210526

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211221

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210726

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200407

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220208

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220121

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20211221

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210726

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200407

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220428

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220503

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220504

End annual number: 3

Start annual number: 1

PG1601 Publication of registration